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Abstract: The potential interaction between clopidogrel and proton pump inhibitors (PPI) 
in patients with acute coronary syndrome (ACS) raises serious concerns for cardiologists. 
However, in patients on this combination of drugs, there is no conclusive evidence of an 
increase  in  adverse  cardiovascular  events.  From  pharmacologic  and  pharmacodynamic 
perspectives, there is a real interaction between clopidogrel and PPIs because of the competitive 
inhibition of CYP2C19 isoenzyme which is required for biotransformation of clopidogrel to 
its active metabolite. The consequent decrease in the availability of this active metabolite leads 
to attenuation of antiplatelet efficacy of clopidogrel. In several observational trials, it was 
shown that decreased antiplatelet effect of clopidogrel due to PPIs may translate into poor 
cardiovascular outcomes. However, an incomplete RCT (COGENT) and a post hoc analysis 
of two large trials (PRINCIPLE-TIMI 44 and TRITON-TIMI 38 trial) showed no significant 
adverse cardiovascular events with this combination. Caution is however needed in patients who 
are hypometabolizers of clopidogrel putting them at a higher risk of adverse coronary events. 
Since 3% of patients are likely to be hypometabolizers of clopidogrel, routine combination of 
clopidogrel and PPIs should be avoided. There is a heightened awareness of this interaction 
following multiple advisory warnings. At the same time, one should not withhold PPIs in 
patients who are at a high risk of developing gastrointestinal (GI) bleeding. In these patients, 
selected choices of PPI such as pantoprazole may be helpful and for low risk patients, serious 
consideration should be given to H2 receptor antagonists or antacids. Therefore, while not 
compromising the cardioprotective effect of antiplatelet agents, the gastroprotective benefit 
of PPI should be strongly considered in patients who need both. Health care providers should 
remain alert to more outcome data. Future researchers will need to demonstrate the safety of 
coadministration of PPIs and clopidogrel and trials should be powered to detect major adverse 
cardiovascular events and facilitate risk stratification based on genetic polymorphism.
Keywords: clopidogrel, proton pump inhibitors (PPIs), acute coronary syndrome (ACS), 
cardiovascular events, anti-platelet agents
Background
Dual antiplatelet therapy (DAT) is a standard of care in the management of unstable 
angina, non-ST elevation myocardial infarction (NSTEMI) and acute coronary 
  syndrome (ACS) undergoing PCI. Long term use of DAT is considered to be important 
for the patency of drug-eluting stents (DES). Furthermore, the antiplatelet action of 
clopidogrel is of critical importance for the reduction of abrupt thrombotic occlusion 
of stents. Hyporesponsiveness to clopidogrel has been found to be an independent 
predictor of cardiovascular events in patients with ACS undergoing percutaneous 
interventions especially in CYP2C19 genetic polymorphism.1–3Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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There is a consensus for the use of prolonged DAT 
regimen after coronary stents especially DES to prevent late 
and very late stent thrombosis. However, there is a concern 
for the increased gastrointestinal (GI) bleed in the setting of 
long term use of DAT, which is the rationale for the use of 
proton pump inhibitors (PPIs). In this setting of long term 
DAT regimen, guidelines suggest the use of PPIs to prevent 
GI bleed. However, there is an ongoing debate about the 
increased major adverse cardiovascular events (MACE) when 
PPIs are used in conjunction with clopidogrel. Recently, the 
US Food and Drug Administration (FDA) has issued a warn-
ing that one of the PPIs (Omeprazole) reduces the antiplatelet 
activity of clopidogrel by 50%. The FDA warning caused a 
debate in the medical community which has often centered 
on the decreased efficacy of clopidogrel with concomitant 
use of PPIs.4,5
Rationale for the use of PPis with DAT
By virtue of their aggregation and homeostasis properties, 
platelets play a pivotal role in the repair of damaged 
vascular endothelium. A DAT regimen impairs the role of 
early homeostasis and the healing of gastric erosions when 
used along with other medications such as nonsteroidal 
anti-inflammatory drugs (NSAID) and acetylsalicylic acid 
(ASA).6 This issue of increased bleeding has been noted 
in the initial trials of ACS such as CAPRIE7 (Clopidogrel 
versus Aspirin in Patients at Risk of Ischemic events), 
CURE8 (Clopidogrel in Unstable Angina to prevent 
Recurrent Events), CHARISMA9 (The Clopidogrel for 
High atherothrombotic Risk and Ischemic Stabilization, 
Management, and Avoidance), and MATCH10 (Management 
of Atherosclerosis with Clopidogrel in High risk patients). 
Recent evidence indicated that the dual anti-platelet regimen 
was the most significant risk factor associated with serious 
and fatal GI bleeding in high risk survivors of myocardial 
infarction.11 As described in the guidelines,6 PPIs are the 
preferred agents for both prophylaxis and treatment of 
GI side effect of DAT regimen. The consensus document 
therefore advocates the use of PPIs in ACS patients with a 
history of GI bleed.
Concerns regarding the use  
of clopidogrel with PPis
Recently, there has been controversy and intense debate 
over the increased MACE with concurrent use of PPIs with 
clopidogrel in the treatment of CAD.12–14 There is a growing 
body of evidence that PPIs may diminish the anti-platelet 
activity of clopidogrel. Furthermore, the concern regarding 
the concurrent use of PPIs and clopidogrel has grown due 
to the widespread use of PPIs and recent FDA advisory 
regarding the interaction of omeprazole and clopidogrel. 
The increased MACE may be due to decreased antiplatelet 
effect of clopidogrel with concomitant use of PPIs as noted 
in the FDA Advisory, which can be accessed at (http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm204253.htm.)
While DAT regimen with clopidogrel and aspirin has 
been shown to significantly lower the cardiovascular events 
in patient undergoing PCI, a significant number of events 
still occur in this population15 and these events may be due 
to suboptimal platelet inhibition in certain subset of patients 
taking the combination of clopidogrel and PPIs.5 The conse-
quent variable platelet response in these patients predisposes 
them to early or late stent thrombosis. The other factors for 
platelet hyporesponsiveness include noncompliance with 
medications and genetic predisposition. Therefore, Sharma 
et al5 have suggested the use of a platelet function test in 
patients with high risk of stent thrombosis or where it is felt 
that concomitant use of PPIs may be causing a significant 
interaction.
Understanding PPi interaction  
with clopidogrel
To appreciate the PPI-clopidogrel interaction, one needs to 
understand the metabolic pathways and pharmacokinetics of 
these drugs. The genetic cause for variable pharmacokinetic 
responses can be measured by differences in plasma 
concentration of active metabolites, and variable phar-
macodynamic response is measured as differences in the 
extent of maximal platelet aggregation based on exposure to 
active metabolites by platelet function testing. Clopidogrel 
is a potent anti-platelet agent whose action is mediated by 
irreversible inhibition of purinergic receptor P2Y12.16,17 
It is a prodrug and requires two-step oxidation by hepatic 
cytochrome P450 enzyme system to convert clopidogrel 
into an active metabolite. This active metabolite works 
on the ADP receptors of platelets for its efficacy. These 
two oxidation steps involve CYP3A, CYP2B6, CYP2C9, 
and CYP2C19 isoenzymes.18,19 Biotransformation of 
clopidogrel has two competing metabolic pathways with 
the first major pathway leading to 85% of the drug being 
inactivated by plasma esterases and the remaining 15% 
undergoing two oxidative steps for conversion into the active 
metabolite. Both of these steps require CYP2C19 for the 
biotransformation of clopidogrel to its active metabolite. 
Juurlink et al13 estimated that CYP2C19 inhibiting PPIs Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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collectively were associated with a 40% relative increase in 
recurrent myocardial infarction.13 The exception is panto-
prazole which has higher inhibition of CYP2C9 rather than 
CYP2C19,20 which may be why pantoprazole is a preferable 
PPI agent by virtue of it being a less competitive inhibitor 
of CYP2C19 than other PPIs.
In vitro study researchers have also demonstrated 
an association of this polymorphism in individuals with 
certain hypofunctioning alleles (loss of Function allele) of 
CYP2C19 and a diminished pharmacodynamic response 
measured by platelet function testing.21 This change in 
pharmacokinetic and pharmacodynamic response was most 
seen in CYP2C19 genetic polymorphism which is involved 
in both the sequential oxidative steps of clopidogrel prior to 
generation of its active metabolite.
Simon et al17 investigated clinical events including death 
from any cause, AMI, and nonfatal stroke at one year in 
a group of 2,207 patients with genetic polymorphism of 
CYP2C19. In individuals with hypofunctioning CYP2C19 
alleles, clinical events were significantly higher; 21.5% 
versus 13.3% when compared to noncarriers. Furthermore, 
in subgroups that underwent PCI, cardiovascular events were 
3.58 times more likely in carriers of hypofunctioning alleles 
than noncarriers. Mega et al1 investigated the association of 
CYP2C19 and plasma concentration of clopidogrel metabolite 
with its resultant effect on platelet function in healthy 
volunteers and then evaluated the association of genetic role 
of CYP2C19 polymorphism and cardiovascular outcomes in 
a subgroup of 1,477 patients in TRITON-TIMI-38 (trial to 
assess improvement in therapeutic outcome by optimizing 
platelet inhibition with prasugrel TIMI-38).22 Carriers with 
one hypofunctioning allele of CYP2C19 had decreased level 
of clopidogrel metabolite with reduction in anti-platelet 
activity by platelet function testing. Consequently, there 
was an increased risk of cardiovascular death, AMI, or 
stroke in carriers of hypofunctioning CYP2C19 alleles and 
those with the CYP2C19*2 allele had a threefold increase 
of stent thrombosis. These differences were seen soon after 
administration of clopidogrel. These study results clearly 
demonstrate the impact of CYP2C19 isoenzymes on the 
anti-platelet activity of clopidogrel.
Drugs which interfere with function of CYP2C19 may 
alter the active metabolite of clopidogrel and thereby adversely 
impacting its antiplatelet activity. PPIs are thought to dimin-
ish the activity of clopidogrel via competitive inhibition 
of CYP2C19 isoenzymes. Other drugs which compete for 
the same isoenzymes for their biotransformation can also 
impact the generation of active clopidogrel metabolite. In 
this instance, clopidogrel and PPIs have to compete for same 
isoenzyme (CYP2C19) which is involved in both of the oxida-
tive steps for biotransformation of clopidogrel into its active 
metabolite. This may lead to a variable response in platelet 
aggregation. In vitro, varying degrees of CYP2C19 inhibition 
have been demonstrated by different PPIs.20 PPIs are competi-
tive inhibitors of CYP2C19 to a varying degree, maximally 
with esomeprazole, followed by omeprazole, pantoprazole, 
and rabeprazole.20 These findings provide a possible expla-
nation for the hypothesis that different PPIs diminish anti-
platelet activity of clopidogrel to a varying degree and this 
interaction leads to decreased inhibition of platelet activation 
as reflected in platelet function testing.
The role of the concurrent use of PPIs with clopidogrel 
and their effect on platelet function were assessed in 
the analysis of PRINCIPLE-TIMI-44 data (Prasugrel 
In Comparison to Clopidogrel for Inhibition of Platelet 
activation and Aggregation)23 and TRITON-TIMI-3822 
and it was found that PPIs lowered inhibition of plate-
let aggregation (IPA) significantly in patents taking a 
PPI and clopidogrel simultaneously.24 Therefore, drug 
interactions and genetic variation in CYP3A4, CYP3A5, 
and CYP2C19 are implicated in the decrease of active 
clopidogrel metabolite production. This has lead to 
CYP2C19 genotyping recommendations in patients with 
concurrent use of clopidogrel and CYP2C19 inhibitors.25 
Similarly, drugs which are potent inhibitors of CYP2C19 
isoenzyme could be expected to have a similar effect on 
the generation of active clopidogrel metabolites. Several 
other drugs may interfere with production of clopidogrel 
metabolites and decrease platelet function inhibition. These 
include cimetidine, etravirine, fluoxetine, fluconazole, 
ketoconazole, variconazole, felbamate, fluvoxamime, and 
ticlopidine.
As initially demonstrated by Gilard et al this potential 
interaction was most notable with PPIs.26 These authors 
evaluated the efficacy of an anti-platelet regimen by 
monitoring the platelet function testing by VASP – one of sev-
eral commercially available tests to check platelet function. 
This was an observational study including 105 consecutive 
patients receiving aspirin and clopidogrel after coronary 
artery stenting. All patients had IPA tests by VASP to 
study possible interactions between clopidogrel and use of 
concomitant drugs such as statins, B-blockers, angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), and PPIs. Only in PPI users was higher 
platelet reactivity by VASP testing found as compared to 
nonusers (61.4 ± 23.3 versus 49.5 ± 16.3).26Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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After the initial observation of potential interaction of 
clopidogrel and PPIs, Gilard et al tested the hypothesis of 
potential PPI interaction with clopidogrel in a randomized 
trial; Omeprazole Clopidogrel Aspirin study (OCLA).27 
In this trial 124 patients undergoing PCI with a loading 
dose of 300 mg of clopidogrel with ASA and maintenance 
therapy were randomized to omeprazole 20 mg or placebo. 
Platelet Reactivity Index (PRI) by VASP has been shown 
to be predictive of MACE after percutaneous coronary 
interventions (PCI).28 In this study, PRI was measured at 
7 days and there was a significantly higher proportion of 
clopidogrel nonresponders defined as PRI . 50% in the 
omeprazole group (60.9% versus 39.8%) by platelet function 
testing with VASP (P , 0.0001) although in a similar study, 
Siller-Matula et al also evaluated interaction of clopidogrel 
with two other PPIs: esomeprazole and pantoprazole and did 
not find any significant difference in PRI.29
Another retrospective study involved a database of Aetna 
Insurance patients where the insurance company reviewed 
its large medical and pharmacy database of patients with 
AMI who were taking clopidogrel with PPIs.30 The database 
was divided into three groups; the first group with AMI took 
clopidogrel without PPI, used as control; the second group 
had low exposure to PPI (less than 182 days), and a third 
group had a higher exposure to PPI (more than 182 days). 
Event rates of MI were calculated at 1 year in these three 
groups; MI in Group 1 was 1.38%, in group 2 was 3.08%, 
and in Group 3 was 5.03%. When adjusted for comorbidities 
such as ischemic heart disease, hypertension, congestive 
heart failure (CHF), dyslipidemia, and diabetes mellitus, the 
differences remained significant among control and higher 
exposure groups (P , 0.05). However, this study had the 
inherent limitation of database studies.
The Clopidogrel Medco Outcome Study was a ret-
rospective study of medical and pharmacy claims using 
National Medco Integrated Database file.31 This was a 
large database with 14,383 patients who had PCI and stent 
deployment during the 1-year period of 2005–2006 and 
followed for another year for cardiovascular events. There 
was a significantly higher MACE in patients taking PPIs in 
conjunction with clopidogrel. This was evident in the group 
with a history of prior MI (39.8% versus 26.2%) or the group 
without prior MI (32.5% versus 21.2%).
Another population based and case controlled Ontario 
study carried out in Canada13 was also used to investigate 
the relationship between the clopidogrel–PPI combination 
and cardiovascular outcomes. Patients aged 66 years or 
more with acute MI who were discharged on clopidogrel 
formed the sample. Investigators reviewed the rate of repeat 
hospitalization among patients who filled prescription of 
clopidogrel after MI without PPI and these patients were 
matched with patients who filled prescription of clopidogrel 
with PPI. After extensive multivariate analysis (MANOVA), 
a significant correlation between readmission for MI and 
clopidogrel–PPI use was noted as compared to the group 
without use of PPI. This was a population-based study with 
its inherent flaws and without adjustment for ethnicity, 
possible polymorphism, or noncompliance. Subanalysis of 
this data, based on the usage of different PPIs showed that 
pantoprazole, in conjunction with clopidogrel, did not lead 
to increased incidence of MI.
The significance of interaction between clopidogrel and 
PPIs was also investigated in a Veterans Health Administration 
study and the results were published in March 2009.14 This 
was also a retrospective cohort study of 8,205 patients pre-
senting with ACS from several veterans hospitals across 
the country during a period of 2003–2006. The data were 
analyzed for all cause mortality or rehospitalization for ACS 
among two groups; patients taking clopidogrel with PPI and 
those taking clopidogrel without PPI. In this study, 59.7% 
of patients were taking omeprazole. All cause mortality or 
rehospitalization for ACS was higher in the PPI group (29.8% 
versus 20.8%) and also in this group recurrent hospitalization 
was higher than that of non-PPI group (14.6% versus 6.9%, 
P , 0.001). Additionally, repeat revascularization was higher 
in the PPI group (15.5% versus 11.9%).
Further analysis of National Medco Integrated Database 
by Stanek and Flockhart32 was presented at the SCAI sci-
entific session of 2009. This study included 16,690 patients 
who received clopidogrel and PPIs within one month of stent 
deployment (BMS or DES) and were followed for 12 months. 
In this study, the use of PPIs together with clopidogrel 
increased MACE (25.1% versus 17.9%, respectively). There 
were enough patients to assess risk stratification for individual 
PPIs and the increased risk was seen among all PPIs includ-
ing pantoprazole as compared to the earlier Canadian study. 
The subanalysis of CREDO data was performed to assess 
the effect of PPI–clopidogrel interaction at 28 days and in 
one year after PCI and this data was presented as an abstract 
at the 2008 AHA.33 Clopidogrel reduced the MACE (death, 
MI, stroke) at 1 year regardless the use of PPI; however PPI 
use was independently associated with an increased 28 day 
MI/death and TVR.
While there are many clopidogrel–PPI studies which 
raise concern, others provide reassurance for use of PPI in Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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such patients. Simon et al17 demonstrated that use of PPIs 
had no effect on overall clopidogrel efficacy in a study which 
was designed to determine the clinical effect of genetic 
polymorphism in patients taking clopidogrel after MI. The 
association between PPI use, IPA, and clinical outcome was 
assessed by an analysis of the PRINCIPLE-TIMI-44 and 
TRITON-TIMI-38 trials by O’Donoghue et al.24 In these 
studies, no association was found between the use of PPIs and 
clinical outcomes for patients treated with clopidogrel and 
prasugrel. In this study, 33% of patients were taking PPIs at 
base line with a majority being on pantoprazole and omepra-
zole. These studies did not support avoidance of concomitant 
use of PPIs with clopidogrel and prasugrel.
The only prospective randomized control trial in 
which the clinical impact of the interaction between 
clopidogrel and omeprazole was assessed was recently 
presented at TCT 2009.34 This trial, named Clopidogrel 
and optimization of Gastrointestinal events (COGENT), 
was a Phase III randomized double control trial which 
was designed to compare combination of clopidogrel and 
omeprazole (single pill CGT-2168 with clopidogrel 75 mg 
and omeprazole 20 mg) with clopidogrel. This study was 
prematurely terminated due to lack of funding after only 
3,627 of a planned 5,000 patients had participated and the 
data were analyzed and presented after a mean follow up 
of 133 days. This analysis included 136 adjudicated car-
diovascular events and 105 adjudicated GI events. It was 
reassuring that there was no clinically significant difference 
in MACE (cardiovascular death, nonfatal MI, CABG/PCI, 
or ischemic stroke) between the groups. However, there was 
a significant reduction in gastrointestinal events in patients 
who were on the combination treatment of clopidogrel and 
omeprazole. Although this is reassuring, this study is not 
powered enough to detect any differences in MACE due to 
early termination. Moreover, the combination of clopidogrel 
and omeprazole (CGT 2168) was a special formulation 
and may not have the same pharmacokinetic and pharma-
cogenomic effects as clopidogrel and omeprazole taken 
separately. Furthermore, the investigators pointed out the 
limitations of decision making based solely on observational 
studies. COGENT investigators indicated that combination 
of PPI with clopidogrel was harmless and decreased the 
incidence of GI bleed. The GI bleed-reducing benefit of 
PPIs in patients using a DAT regimen was also highlighted 
in a recent retrospective cohort study by Ray et al.35 These 
researchers showed that concomitant use of PPI with   
clopidogrel in CAD is associated with fewer hospitaliza-
tions for gastrointestinal bleeds. Another recent retrospec-
tive review of PCI between 2001–200736 included a total 
of 2,646 patients on a DAT regimen after PCI and 28% of 
these patients were discharged on PPIs. In groups with or 
without PPI use, no differences in cardiovascular outcomes 
were noted. Interestingly, MACE was actually lower in the 
omeprazole and esomeprazole groups. The PPI–clopidogrel 
interaction was addressed in a recent meta-analysis of 
93,278 patients37 where investigators aimed to grade all 
the studies from relatively low quality to higher-quality 
evidence. Notably, as the quality of evidence improved, the 
risk of PPI–clopidogrel interaction was not as apparent. The 
randomized trial participants showed no significant differ-
ences in adverse cardiovascular risks. There is a clear need 
for more studies to address this issue and to investigate 
effects of individual PPIs on clopidogrel efficacy. Such 
studies should also involve investigations of the genetic 
components of hypofunctioning CYP2C19 alleles.
Advisory warnings
An intense controversy has arisen regarding concurrent 
use of PPIs and clopidogrel. In spite of strong evidence 
for minimal or no interaction from prospective trials, 
government authorities such as the US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMEA) have issued statements regarding the potential 
interaction of concomitant use of clopidogrel and PPIs.38,39 
The initial FDA announcement on January 2009 cautioned 
health care professionals about prescribing omeprazole 
and clopidogrel and health care workers were urged to 
reevaluate the need for continuing treatment with PPI 
including PRILOSEC OTC. Subsequently, presentation 
of the Clopidogrel Medco Outcome study32 at the SCAI 
2009 led to an advisory by SCAI. While acknowledging 
the need for further studies, SCAI urged cardiologists to 
consider using H2 receptor antagonists or antacids instead 
of PPI in patients with DAT therapy after PCI. Furthermore, 
the FDA issued an advisory statement on March 12th 
2010 after a crossover study in 40 healthy participants, 10 
each in the four CYP2C19 metabolizer groups, required 
by FDA and carried out by a manufacturer. In this study 
pharmacokinetics and antiplatelet effects of clopidogrel 
were investigated in 40 healthy volunteers with four metabo-
lizer groups; ultra-rapid metabolizer, extensive metabolizer, 
intermediate metabolizer, and poor metabolizer. Each group 
of 10 volunteers were randomly assigned to two types of 
treatments: 300 mg loading followed by maintenance dose 
of 75 mg, or loading of 600 mg and maintenance dose of 
150 mg.25 Based on this crossover study, the FDA required Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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a boxed warning for clopidogrel to caution that poor 
metabolizers of clopidogrel may not receive full protection 
from MI, stroke, and cardiovascular death. The boxed 
warning further states that tests are available to determine 
genetic profile of CYP2C19 isoenzymes to predict if patients 
will ineffectively convert clopidogrel to active metabolite. 
The FDA advised health care workers to consider an alter-
native anti-platelet regimen or alternative dosing strategies 
of clopidogrel in such poor metabolizers.
Fact or fiction
The current studies suggesting a possible interaction between 
clopidogrel and PPIs raise a serious concern without any 
definite conclusion. From a pharmacologic perspective, this 
interaction is a reality with uncertain clinical implications. In 
certain subgroups, coadministration of PPIs and clopidogrel 
may be harmful. There are a strong pharmacodynamic data 
suggesting that the interaction between clopidogrel and PPI 
exists, especially with omeprazole. This may lead to attenu-
ation of the anti-platelet effect of clopidogrel as measured 
by IPA testing. While the importance of routine platelet 
functions testing may be uncertain, it may be useful in high 
risk patients to assure the adequacy of platelet inhibition.5 
Accumulating data support the hypothesis that suboptimal 
platelet inhibition may translate into adverse cardiovascular 
events. Future studies will be needed to investigate effect 
of individual PPI interaction with clopidogrel. Research-
ers will also need to address the role of genetics in this 
interaction.
However, the reality of clinical practice is that while we 
wait for such studies, we still need to make daily decisions 
on our patients. It is prudent that PPIs not be the routine 
practice in patients on DAT therapy until further data are 
available and an alternative approach for GI prophylaxis 
should be considered such as ranitidine or famotidine 
(Pepcid).6 Pepcid has been shown to be effective in the 
prevention of gastric and duodenal ulcers and esophagitis 
in patients taking ASA.40 Alternatively, if a PPI is required, 
newer thienopyridine agents such as prasugrel may be 
considered.
Observational studies could be used to establish an 
association and generate hypotheses which need to be 
tested in randomized controlled trials. Therefore, in view 
of discordant results among many observational studies 
and the only incomplete randomized controlled study, 
there is a great need for further randomized controlled 
studies.
Management strategies
Multiple warnings have heightened the awareness of 
PPI-clopidogrel interaction. On March 12th 2010, the FDA 
approved a third label change for clopidogrel with a “boxed 
warning” regarding diminished clopidogrel efficacy in 
patients with decreased CYP2C19 function due to genetic 
polymorphism. Recently, the American College of Cardiology 
Task Force published a clinical expert consensus document 
to make recommendations for practicing physicians relating 
to this issue.41,42 Therefore, one should avoid combining 
clopidogrel and PPIs unless there is a compelling indication. 
One should also keep in mind that there is a 3% prevalence 
of poor metabolizers.25 At the same time, it is prudent not 
to withhold PPIs in patients at high risk for GI bleeding. In 
these patients, pantoprazole may be the PPI of choice. For 
low risk patients, serious consideration should be given to 
H2 receptor antagonists or antacids. Patients should also be 
advised to avoid self-medicating with omeprazole while they 
are on clopidogrel. They should also be educated about the 
possible interaction between PPIs and clopidogrel and the 
risk of ACS in such settings. It is now accepted that genetic 
polymorphism of CYPC219 decreases the active metabolite 
of clopidogrel, leading to a decrease in antiplatelet activity. 
In such situations, an alternate anti-platelet agent such as 
prasugrel may be needed. Prasugrel is also a prodrug which 
was shown to reduce ischemic events and stent thrombosis in 
the TRITON-TIMI-38 trial.22 This drug has not been shown 
to have a significant interaction from CYP2C19 enzyme 
polymorphism.43 Use of prasugrel may be a good alternative 
in patients known to be poor metabolizers or poor to interme-
diate metabolizers requiring PPIs for GI bleed prophylaxis. 
Irrespective of advisories, the benefits of PPIs in the GI 
bleed prophylaxis should not be overlooked.35 Therefore, in 
ACS patients at risk for GI bleed, the cardioprotective ben-
efit of clopidogrel and the gastroprotective effects of PPIs 
should be kept in mind. By COGENT, post hoc analysis of 
PRINCIPLE-TIMI-44 and TRITON-TIMI-38 trials showed 
no pharmacodynamic interaction of clopidogrel with PPIs nor 
any adverse cardiovascular outcomes. However, health care 
providers should remain on high alert as further data unfolds. 
The statement and guidelines for physicians published by 
ACCF/AHA task force on clopidogrel clinical alert are of 
great interest.41,42 The expert panel feels that a majority of 
ACS/coronary stent patients on clopidogrel do well without 
a need for genetic or platelet function testing. However, 
a minority of patients especially the high risk group may 
be prone to adverse clinical events such as cardiovascular Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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and/or cerebrovascular ischemic and/or hemorrhagic events 
due to a significant variability in individual responses to 
clopidogrel. This variability in platelet function response to 
clopidogrel is due to genetic polymorphism of CYP2C19 
and occasionally genetic polymorphism of ABCB1 may 
also play a role. Loss of function may be due to CYP2C19*2 
or *3 (poor metabolizers) and conversely gain of function 
may be due to CYP2C19*17 variant (hyper-rapid or ultra-
rapid metabolizers). However, some experts argue that the 
predictive value of genetic variant testing is as low as 12% 
to 20%. Obviously, multiple nongenetic factors including 
noncompliance with clopidogrel and a concomitant use 
of PPIs may play a significant role. Therefore, there is no 
expert consensus on routine genetic or platelet function 
testing. However, certain guidelines have been proposed in 
high risk patients who have the following clinical conditions: 
diabetes mellitus, chronic renal failure, diffuse three vessels, 
left main disease, and diffuse cerebrovascular atherosclerotic 
disease. In these patients, the expert panel recommends that 
genetic or platelet function testing should be considered to 
identify and adequately treat clopidogrel hyporesponders. 
Alternatively, clinicians may empirically double the dose 
of clopidogrel and other steps include usage of other agents 
such as prasugrel and ticagrelor (when approved), as these 
are not influenced by CYP2C19 genetic variants. However, 
there is potential bleeding issue with some of these agents 
and, in fact, prasugrel is contraindicated in patients who have 
experienced strokes. Finally, consideration should be given 
to cilostazol addition to clopidogrel and ASA regimen.44 In 
rare instances, cilostazol may be used alone,45,46 however, the 
concern for inadequate platelet inhibition remains. Therefore, 
platelet function testing may prove to be an ideal way of 
ensuring the therapeutic range of platelet function inhibition 
in various clinical situations.
Conclusion
In several observation studies, it has been suggested that a 
true pharmacologic interaction exists between clopidogrel 
and PPIs. Pharmacodynamic data suggest that competitive 
inhibition of CYP2C19 by PPIs decreases the availability of 
the active metabolite of clopidogrel and therefore diminishes 
its anti-platelet efficacy. This attenuation of anti-platelet effect 
of clopidogrel in conjunction with PPI has been supported 
in many platelet function studies and recent data has further 
shown that the decreased anti-platelet effect of clopidogrel 
translates into adverse cardiovascular outcomes. Therefore, 
routine use of PPIs should be avoided. Even though the 
results of the MEDCO study32 suggested interaction of all 
PPIs with clopidogrel, the Ontario study13 did not show an 
increase in MACE with pantoprazole because of its minimal 
effect on CYP2C19. Therefore, there is growing support for 
pantoprazole as the PPI of choice with clopidogrel therapy.
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